Pulmonary Alveolar Proteinosis - 24 Studies Found
Active, not recruiting |
: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan : Pulmonary Alveolar Proteinosis, Autoimmune : 2016-07-13 :
|
Not yet recruiting |
: Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis : Autoimmune Pulmonary Alveolar Proteinosis : 2016-11-28 : Drug: Sargramostim Other Names:
|
Recruiting |
: Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) : Autoimmune Pulmonary Alveolar Proteinosis : 2016-02-28 :
|
Recruiting |
: Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis :
: 2007-10-31 : Drug: rituximab IV, 1000 mg, two weeks, 2 times Othe |
Recruiting |
: Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. : Pulmonary Alveolar Proteinosis : 2013-11-07 :
|
Recruiting |
: Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT : Pulmonary Alveolar Proteinosis : 2014-02-12 |
Completed |
: SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study : Pulmonary Alveolar Proteinosis, Autoimmune : 2016-07-13 : Drug: Sargramostim |
Recruiting |
: Rituximab for Anti-cytokine Autoantibody-Associated Diseases :
: 2013-04-25 : Drug: Rituximab/Rituxan Rituximab is a genetically engineered chimeric murine/human monoclonal antibody |
Completed |
: Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects :
|
Recruiting |
: European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank :
: 2016-07-29 |